Kairos Pharma shareholders approve dilutive stock issuance, elect directors, enter IR pact

Kairos Pharma, LTD.

Entered one-year IR services agreement with Barretto Pacific Corp for $170,000 fee.
Shareholders elected all four director nominees (Yu, Bae, Keyoung, Sighvi).
Ratified Weinberg & Company as independent auditor for FY2025.
Approved issuance of >20% common stock at price below NYSE American minimum price.
Advisory votes approved executive compensation and 1-year frequency.

item 1.01item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.